Free tool
FAERS Monitor: Praxbind
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761025 or its brand name (Praxbind, Idarucizumab). Reports on generic versions are filed under their own applications.
Reports
1,434
Serious
1,398
97% of reports
Hospitalization
517
Death reported
899
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death170
- haemorrhage119
- gastrointestinal haemorrhage81
- cerebral haemorrhage80
- haemorrhage intracranial67
- drug ineffective64
- multiple organ dysfunction syndrome62
- acute kidney injury48
- sepsis46
- ischaemic stroke45
- pneumonia41
- shock haemorrhagic41
- cerebrovascular accident34
- septic shock33
- cardiac failure31
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 6 |
| 2016 | 114 |
| 2017 | 207 |
| 2018 | 309 |
| 2019 | 274 |
| 2020 | 167 |
| 2021 | 140 |
| 2022 | 71 |
| 2023 | 69 |
| 2024 | 40 |
| 2025 | 24 |
| 2026 | 13 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,725 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| shock haemorrhagicSignal | 41 | 74.2 | 54.9 | 2,876 |
| haemorrhage intracranialSignal | 67 | 66.0 | 52.2 | 4,210 |
| ischaemic strokeSignal | 45 | 37.1 | 27.8 | 1,541 |
| cerebral haemorrhageSignal | 80 | 32.8 | 26.5 | 2,437 |
| multiple organ dysfunction syndromeSignal | 62 | 32.2 | 25.2 | 1,840 |
| haemorrhageSignal | 119 | 16.7 | 14.1 | 1,749 |
| gastrointestinal haemorrhageSignal | 81 | 14.2 | 11.5 | 986 |
| septic shockSignal | 33 | 11.1 | 7.9 | 295 |
| sepsisSignal | 46 | 6.1 | 4.6 | 190 |
| cardiac failureSignal | 31 | 5.7 | 4.0 | 115 |
| acute kidney injurySignal | 48 | 4.6 | 3.5 | 133 |
| cerebrovascular accidentSignal | 34 | 2.9 | 2.1 | 42 |
| deathSignal | 170 | 2.9 | 2.5 | 218 |
| pneumonia | 41 | 1.9 | 1.4 | 16 |
| drug ineffective | 64 | 0.7 | 0.6 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.